March 25, 2024
VIA EDGAR AND EMAIL
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Dillon Hagius and Laura Crotty
| Re: | Dianthus Therapeutics, Inc. |
Registration Statement on Form S-1
Filed March 21, 2024
File No. 333-274863
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Dianthus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company be accelerated to 4:15 p.m., Eastern Standard Time, on March 27, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631.
| Very truly yours, | ||
| Dianthus Therapeutics, Inc. | ||
| By: | /s/ Ryan Savitz | |
| Name: | Ryan Savitz | |
| Title: | Chief Financial Officer and Chief Business Officer | |
| cc: | Marino Garcia, Dianthus Therapeutics, Inc. |
Adam Veness, Dianthus Therapeutics, Inc.
Ryan A. Murr, Gibson, Dunn & Crutcher LLP
Branden C. Berns, Gibson, Dunn & Crutcher LLP